|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Tom DiLenge |
Date | 7/20/2015 9:13:33 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
-----Amendment on GE Salmon Labeling
--One Health Legislation (Senate Discussion Draft)
Review and Labeling of Food Derived From Biotechnology
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---U.S. Government Policy
Funding for the USDA
---H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
Potential Regulation of New Genetic Modification Technologies
Funding for Biomass Crop Assistance Program
---H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Trade Promotion Authority
---HR 2146: Bipartisan Congressional Trade Priorities and Accountability Act of 2015
---HR 1295: Trade Adjustment Assistance Act of 2015
Transatlantic Trade and Investment Partnership
---Ag-Biotech Issues
Nutrition Policy
---Reauthorization of Federal School Nutrition Programs (Senate Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Security Council (NSC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Dana |
OBrien |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
----Amendment on GE Salmon Labeling
--One Health Legislation (Senate Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for the USDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for FDA
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for National Institutes of Health
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Biomass Crop Assistance Program
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Sequestration of PDUFA Fees
--HR 2725: Food and Drug Administration Safety over Sequestration Act of 2015
--Implementation of S. 365: Budget Control Act
--S. 1413: FDA User Fee Protection Act
Funding for Renewable Chemicals/Bio-based Products
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biofuels
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Department of Defense Funding of Advanced Biofuels
--H.R. 2685/S.1558: Department of Defense Appropriations Act for FY 2016
--H.R.2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016,
--H.R.2822: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S.1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Erick |
Lutt |
|
|
|
Phyllis |
Arthur |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CAW
16. Specific lobbying issues
IP Rights for Environmental Technologies
--U.S. Government Position for U.N. Convention on Climate Change Negotiations
17. House(s) of Congress and Federal agencies Check if None
U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tom |
DiLenge |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Renewable Chemicals/Bio-based Products (Non-Funding)
--Expansion of Master Limited Partnerships to Renewable Chemicals
--H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015
--Investment Tax Credit for Renewable Chemicals and Bio-based Products
--New Production Tax Credit
--S. 1447: Sustainable Chemistry Research and Development Act
--S. 697: Chemical Safety for the 21st Century Act
Funding for Renewable Chemicals/Bio-based Products and Biorefineries
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014, Energy Title IX, Section 9003
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Rina |
Singh |
|
|
|
Tom |
DiLenge |
|
|
|
Erick |
Lutt |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
--H.R. 9: Innovation Act
--Implementation of the America Invents Act of 2011
--S.1137: The PATENTS Act of 2015
Trans-Pacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
--Intellectual Property Issues
Patenting of Biological Inventions
--DNA Patenting and Licensing
Trade Promotion Authority
--HR 2146: Bipartisan Congressional Trade Priorities and Accountability Act of 2015
--HR 1295: Trade Adjustment Assistance Act of 2015
Inter Partes Review
--H.R. 2578: Commerce, Science, Justice and Related Agencies Appropriations Act of FY 2016
--Implementation of the American Invents Act of 2011
--S. 1137: The PATENTS Act of 2015
--S. 632: STRONG Patents Act of 2011
--H.R. 9: Innovation Act
Colombia National Development Plan
--Intellectual Property Issues
IP Rights for Environmental Technologies
--U.S. Government Position for U.N. Convention on Climate Change Negotiations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC), Office of the Vice President of the United States, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Charles |
Fritts |
|
|
|
Derrick |
White |
|
|
|
Hans |
Sauer |
|
|
|
Jamie |
Gregorian |
|
|
|
Joseph |
Damond |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
--Implementation of the Agricultural Act of 2014
--Production Tax Credit Extension
--Renewable Fuel Standard
Funding for Biomass Crop Assistance Program
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products and Biorefineries
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014, Energy Title IX, Section 9003
Funding for Biofuels
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Department of Defense Funding of Advanced Biofuels
--H.R. 2685/S.1558: Department of Defense Appropriations Act for FY 2016,
--H.R. 2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--H.R.2822: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Environmental Protection Agency (EPA), Agriculture - Dept of (USDA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
----Amendment on GE Salmon Labeling
--One Health Legislation (Senate Discussion Draft)
Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--U.S. Government Policy
Nutrition Policy
--Reauthorization of Federal School Nutrition Programs (Senate Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracey |
LaTurner |
|
|
|
Dana |
OBrien |
|
|
|
Catharine |
Harris |
|
|
|
Matthew |
OMara |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
--Implementation of the Agricultural Act of 2014
--Production Tax Credit Extension
--Renewable Fuel Standard
Funding for Biomass Crop Assistance Program
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products and Biorefineries
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014, Energy Title IX, Section 9003
Funding for Biofuels
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
--Department of Defense Funding of Advanced Biofuels
--H.R. 2685/S.1558: Department of Defense Appropriations Act for FY 2016,
--H.R.2028: Energy and Water Development and Related Agencies Appropriations Act for FY 2016
--H.R.2822: Department of the Interior, Environment, and Related Agencies Appropriations Act for FY 2016
--Implementation of the Agricultural Act of 2014
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Genetically Engineered (GE) Animals
--One Health Legislation (Senate Discussion Draft)
--H.R. 3049/S.1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
----Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
--H.R. 1599: Safe and Accurate Food Labeling Act of 2015
--U.S. Government Policy
Biosimilars
--Implementation of Affordable Care Act
--Interchangeability and Pharmacy Substitution
--Naming
--Reimbursement Policy
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Dana |
OBrien |
|
|
|
Derrick |
White |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeffrey |
Peters |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars
--Naming
--Interchangeability and Pharmacy Substitution
--Implementation of Affordable Care Act
--Patent Certification
--Reimbursement Policy
Funding for National Institutes of Health
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
340B Drug Pricing Program
--Program Implementation & Oversight
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations
--Implementation of Affordable Care Act
Funding for FDA
--H.R. 3049/S. 1800: Agriculture, Rural Development, FDA, and Related Agencies Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Biodefense Research, Development, and Procurement Issues
Reimbursement for Innovative Products
--Medicare Part D Prescription Drug Program
--Medicare Part B Physician-Administered Products
Sequestration of PDUFA Fees
--HR 1078: Food and Drug Administration Safety over Sequestration Act of 2015
--Implementation of S. 365: Budget Control Act
--S. 1413: FDA User Fee Protection Act
Drug Evaluation and Review
--Implementation of the FDA Safety and Innovation Act/Prescription Drug User Fee Act
Orphan Drug Act Tax Credit
21st Century Cures Initiative
--Biomarkers and Regulatory Science Improvements
--Communication with Healthcare Professionals and Payers
--Expanded Access to Investigational Drugs
--Expedited Pathways
--FDA Hiring Flexibility
--FDA Management and Financial Accountability
--Innovation Incentives
--Longitudinal Study of Chronic Diseases
--Patient Access to Approved Drugs
--Patient-Focused Drug Development
--Use of Real-World Evidence
--Vaccine and Anti-Microbial Resistance Product Development and Incentives
--ADAPT Act (House Discussion Draft)
--DISARM Act (House Discussion Draft)
--Medicare Part D Low-Income Subsidy Increased Co-Pay
--Biosimilars Reimbursement Policy
--Authorized Generics Reimbursement Calculation
--Reimbursement for Infusion Drugs under Medicare Part B
Colombia National Development Plan
--Regulatory Issues
--Intellectual Property Issues
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--ADAPT Act (House Discussion Draft)
--DISARM Act (House Discussion Draft)
Trans-Pacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
--Regulatory Transparency
Transatlantic Trade and Investment Partnership
--Regulatory Harmonization
--Intellectual Property Issues
--Reimbursement Transparency
Medicare Physician Payment Sustainable Growth Rate Formula
--H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Andrew |
Emmett |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Charles |
Fritts |
|
|
|
Derrick |
White |
|
|
|
Cartier |
Esham |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeffrey |
Peters |
|
|
|
Phyllis |
Arthur |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Kathleen |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development, and Procurement Issues (Non-funding)
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--ADAPT Act (House Discussion Draft)
--DISARM Act (House Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Tracey |
LaTurner |
|
|
|
Phyllis |
Arthur |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kathleen |
Holcombe |
|
|
|
Jeffrey |
Peters |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
21st Century Cures Initiative
--Longitudinal Study of Chronic Diseases
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--H.R. 3020/S. 1695: Departments of Labor, HHS, Education, and Related Agencies Appropriations Act for FY 2016
Combating Antibiotic-Resistant Bacteria (CARB) Initiative
--ADAPT Act (House Discussion Draft)
--DISARM Act (House Discussion Draft)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Cartier |
Esham |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeffrey |
Peters |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Kathleen |
Holcombe |
|
|
|
Andrew |
Emmett |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Pricing and Rebates
--Average Manufacturer Price Calculations
--Implementation of Affordable Care Act
Reimbursement for Innovative Products
--Medicare Part D Prescription Drug Program
--Medicare Part B Physician-Administered Products
Medicare Physician Payment Sustainable Growth Rate Formula
--H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015
21st Century Cures Initiative
--Patient Access to Approved Drugs
--Medicare Part D Low-Income Subsidy Increased Co-Pay
--Biosimilars Reimbursement Policy
--Authorized Generics Reimbursement Calculations
--Reimbursement for Infusion Drugs under Medicare Part B
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Medicare Payment Advisory Commission (MedPAC), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Derrick |
White |
|
|
|
Cartier |
Esham |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Jamie |
Gregorian |
|
|
|
Jeffrey |
Peters |
|
|
|
Phyllis |
Arthur |
|
|
|
Brent |
Del Monte |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Kathleen |
Holcombe |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
--Public Company Accounting Oversight Board - Audit Cost Increases
Capital Formation Investment Incentives
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--H.R. 2179: PARTNER Act
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
Expansion of Exemption under SEC Regulation A
--H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
--Fostering Innovation Act (House Discussion Draft)
XBRL Exemption for Small Public Companies
--H.R. 1965: Small Company Disclosure Simplification Act
--H.R. 37: Promoting Job Creation and Reducing Small Business Burdens Act
Capital Market Enhancements
--SEC Office of Small Business Policy Responsibilities
--H.R. 1525: Disclosure Modernization and Simplification Act
--H.R. 1675/S.576: Encouraging Employee Ownership Act
--H.R. 1723: Small Company Simple Registration Act
--H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act
--H.R. 2357: Accelerating Access to Capital Act
Proxy Advisory Services
--Impact of Policies on Small Public Companies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Cartier |
Esham |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Renewable Chemicals/Bio-based Products
--New Production Tax Credit
--Expansion of Master Limited Partnerships to Renewable Chemicals
--H.R. 2833/S.1656: Master Limited Partnerships Parity Act of 2015
Biofuels
--Production Tax Credit Extension
Research & Development Tax Credit Reforms
--Extension
--Permanency
--H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities
--S. 537: COMPETE Act
Capital Formation Investment Incentives
--Reform of Capital Gains Rules
--Reform of Net Operating Loss Rules
--Reform of Passive Loss Rules
--S. 341: Start-up Jobs and Innovation Act
--S. 537: COMPETE Act
--H.R. 2179: PARTNER Act
Tax Reform
--Innovation/Patent Box
Orphan Drug Act Tax Credit
Inversions
--H.R. 2995: Department of Financial Services and Related Agencies Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Derrick |
White |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tracey |
LaTurner |
|
|
|
Brent |
Del Monte |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Foreign Agricultural Biotechnology Laws and Regulations
--China Biotechnology Regulations
--EU Ag Biotech Policies and Regulations
Colombia National Development Plan
--Regulatory Issues
--Intellectual Property Issues
Trans-Pacific Partnership
--Data and Intellectual Property Protections for Pharmaceuticals
--Regulatory Transparency
Transatlantic Trade and Investment Partnership
--Ag-Biotech Issues
--Regulatory Harmonization
--Intellectual Property Issues
--Reimbursement Transparency
Trade Promotion Authority
--H.R. 2146: Bipartisan Congressional Trade Priorities and Accountability Act of 2015
--H.R. 1295: Trade Adjustment Assistance Act of 2015
IP Rights for Environmental Technologies
--U.S. Government Position for U.N. Convention on Climate Change Negotiations
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Natl Security Council (NSC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Dana |
OBrien |
|
|
|
Derrick |
White |
|
|
|
Jeffrey |
Peters |
|
|
|
Joseph |
Damond |
|
|
|
Matthew |
OMara |
|
|
|
Brent |
Del Monte |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |